Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 2.42% | |
| Bearish Engulfing | Bearish | -1.46% | |
| Fell Below 20 DMA | Bearish | -1.46% | |
| Upper Bollinger Band Touch | Strength | -1.46% |
| Alert | Time |
|---|---|
| Non-ADX 1,2,3,4 Pullback Entry | about 19 hours ago |
| 1,2,3, Pullback Entry | about 19 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| 20 DMA Resistance | about 19 hours ago |
| 10 DMA Resistance | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 11/11/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Solid Tumor Cancers Immune Checkpoint Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.97 |
| 52 Week Low | 1.36 |
| Average Volume | 782,199 |
| 200-Day Moving Average | 2.23 |
| 50-Day Moving Average | 2.89 |
| 20-Day Moving Average | 3.49 |
| 10-Day Moving Average | 3.44 |
| Average True Range | 0.28 |
| RSI (14) | 53.27 |
| ADX | 30.73 |
| +DI | 23.90 |
| -DI | 17.63 |
| Chandelier Exit (Long, 3 ATRs) | 3.14 |
| Chandelier Exit (Short, 3 ATRs) | 3.91 |
| Upper Bollinger Bands | 3.81 |
| Lower Bollinger Band | 3.16 |
| Percent B (%b) | 0.34 |
| BandWidth | 18.77 |
| MACD Line | 0.14 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.0518 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.79 | ||||
| Resistance 3 (R3) | 3.81 | 3.71 | 3.72 | ||
| Resistance 2 (R2) | 3.71 | 3.60 | 3.69 | 3.69 | |
| Resistance 1 (R1) | 3.54 | 3.54 | 3.49 | 3.52 | 3.67 |
| Pivot Point | 3.44 | 3.44 | 3.41 | 3.42 | 3.44 |
| Support 1 (S1) | 3.27 | 3.33 | 3.22 | 3.25 | 3.09 |
| Support 2 (S2) | 3.17 | 3.27 | 3.15 | 3.07 | |
| Support 3 (S3) | 3.00 | 3.17 | 3.04 | ||
| Support 4 (S4) | 2.98 |
